AC Immune to Present morADC Platform for Neurodegenerative Diseases at AAIC 2024

AC Immune, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, will present three oral presentations at the Alzheimer’s Association International Conference (AAIC) 2024. This event will take place in Philadelphia, PA, from July 28 to August 1, 2024.

The first presentation, "Discovery and preclinical development of [18F]ACI-19626, a first-in-class TDP-43-PET tracer," will be held on Monday, July 29, 2024, from 2:50 PM to 3:00 PM. Tamara Seredenina, PhD from AC Immune, will discuss the development of this innovative tracer.

The second presentation, "Active immunotherapy, ACI-24.060, induces anti-Abeta antibodies with binding profiles mirroring clinically validated monoclonal antibodies," is scheduled for Tuesday, July 30, 2024, from 9:40 AM to 9:50 PM. Emma Fiorini, PhD from AC Immune, will focus on the immunotherapy ACI-24.060.

The third presentation, "A new class of neurodegenerative disease-fighting drugs: morADC (Morphomer®- Antibody Drug Conjugates)," will be on Wednesday, July 31, 2024, from 8:07 AM to 8:14 AM. Madiha Derouazi, PhD from AC Immune, will introduce the morADC platform.

Additionally, AC Immune will present a poster titled "#18 Comparative analysis of clinical endpoint progression rates in sporadic Alzheimer’s disease and Down Syndrome-related Alzheimer’s disease" on Tuesday, July 30, 2024, from 8:00 AM to 4:15 PM. This poster will be presented by Michael Rafii, MD, PhD from the Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA.

AC Immune SA is a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and other conditions driven by misfolded proteins. The company’s SupraAntigen® and Morphomer® platforms fuel its extensive pipeline, which currently includes sixteen therapeutic and diagnostic programs. Five of these programs are in Phase 2 clinical trials, and one is in Phase 3.

The company has a history of forming strategic partnerships with leading global pharmaceutical companies, securing substantial non-dilutive funding, potential milestone payments, and royalties.

The company’s SupraAntigen® and Morphomer® technology platforms are essential in driving their diversified pipeline of both first-in-class and best-in-class assets.

AC Immune continues to establish itself as a key player in the precision medicine field for neurodegenerative diseases, backed by its proprietary technology platforms and strategic collaborations. The upcoming presentations at AAIC 2024 highlight the company's ongoing efforts and innovations in tackling some of the most challenging neurodegenerative diseases today.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!